Morgan Stanley’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$770M Buy
2,629,104
+107,981
+4% +$35.5M 0.05% 388
2025
Q4
$884M Sell
2,521,123
-162,527
-6% -$54.9M 0.05% 329
2025
Q3
$867M Sell
2,683,650
-355,815
-12% -$111M 0.05% 336
2025
Q2
$1.18B Buy
3,039,465
+66,356
+2% +$26.7M 0.08% 228
2025
Q1
$1.29B Buy
2,973,109
+104,911
+4% +$42.1M 0.09% 195
2024
Q4
$1.06B Sell
2,868,198
-584,569
-17% -$245M 0.07% 234
2024
Q3
$1.8B Buy
3,452,767
+225,768
+7% +$121M 0.13% 140
2024
Q2
$1.75B Buy
3,226,999
+273,155
+9% +$144M 0.14% 141
2024
Q1
$1.53B Sell
2,953,844
-2,853,526
-49% -$1.42B 0.12% 159
2023
Q4
$2.74B Buy
5,807,370
+3,022,656
+109% +$1.4B 0.12% 158
2023
Q3
$1.21B Buy
2,784,714
+46,322
+2% +$21M 0.12% 150
2023
Q2
$1.22B Sell
2,738,392
-24,049
-0.9% -$11.1M 0.12% 161
2023
Q1
$1.27B Sell
2,762,441
-180,764
-6% -$86M 0.14% 147
2022
Q4
$1.51B Buy
2,943,205
+465,102
+19% +$236M 0.17% 123
2022
Q3
$1.13B Buy
2,478,103
+18,094
+0.7% +$8.66M 0.15% 132
2022
Q2
$1.19B Buy
2,460,009
+980,223
+66% +$485M 0.15% 135
2022
Q1
$727M Sell
1,479,786
-221,355
-13% -$101M 0.1% 202
2021
Q4
$789M Buy
1,701,141
+51,202
+3% +$21.5M 0.1% 209
2021
Q3
$615M Buy
1,649,939
+81,314
+5% +$30.9M 0.08% 227
2021
Q2
$599M Buy
1,568,625
+113,659
+8% +$43.4M 0.08% 226
2021
Q1
$522M Sell
1,454,966
-103,998
-7% -$33.4M 0.08% 242
2020
Q4
$501M Buy
1,558,964
+274,659
+21% +$84.3M 0.08% 229
2020
Q3
$345M Buy
1,284,305
+32,411
+3% +$8.72M 0.07% 258
2020
Q2
$329M Sell
1,251,894
-91,031
-7% -$24.3M 0.07% 243
2020
Q1
$305M Buy
1,342,925
+70,925
+6% +$19.3M 0.08% 212
2019
Q4
$384M Buy
1,272,000
+5,294
+0.4% +$1.46M 0.09% 214
2019
Q3
$304M Buy
1,266,706
+84,298
+7% +$23.1M 0.08% 248
2019
Q2
$334M Buy
1,182,408
+378,897
+47% +$104M 0.09% 231
2019
Q1
$231M Sell
803,511
-148,679
-16% -$43M 0.07% 298
2018
Q4
$250M Buy
952,190
+275,378
+41% +$75.7M 0.07% 270
2018
Q3
$185M Buy
676,812
+268,900
+66% +$69.8M 0.05% 375
2018
Q2
$97.1M Sell
407,912
-38,333
-9% -$8.88M 0.03% 589
2018
Q1
$98M Sell
446,245
-139,587
-24% -$32.8M 0.03% 604
2017
Q4
$132M Sell
585,832
-131,611
-18% -$28M 0.04% 485
2017
Q3
$136M Buy
717,443
+111,949
+18% +$21.3M 0.04% 433
2017
Q2
$114M Sell
605,494
-388,008
-39% -$69.7M 0.03% 513
2017
Q1
$164M Buy
993,502
+142,818
+17% +$22.7M 0.05% 376
2016
Q4
$122M Buy
850,684
+347,684
+69% +$46.6M 0.04% 458
2016
Q3
$63M Buy
503,000
+20,322
+4% +$2.62M 0.02% 730
2016
Q2
$63.4M Buy
482,678
+76,098
+19% +$10.4M 0.02% 681
2016
Q1
$56.5M Sell
406,580
-78,069
-16% -$10.4M 0.02% 696
2015
Q4
$67.6M Buy
484,649
+29,711
+7% +$4.09M 0.02% 652
2015
Q3
$63.7M Sell
454,938
-719,221
-61% -$108M 0.02% 665
2015
Q2
$193M Buy
1,174,159
+467,723
+66% +$74.7M 0.07% 314
2015
Q1
$109M Sell
706,436
-716,020
-50% -$102M 0.04% 478
2014
Q4
$179M Buy
1,422,456
+342,199
+32% +$42.3M 0.07% 320
2014
Q3
$129M Buy
1,080,257
+167,248
+18% +$19.2M 0.05% 415
2014
Q2
$98.3M Buy
913,009
+28,208
+3% +$2.91M 0.04% 521
2014
Q1
$88.1M Sell
884,801
-99,411
-10% -$8.99M 0.04% 517
2013
Q4
$90.9M Buy
984,212
+41,079
+4% +$3.65M 0.04% 491
2013
Q3
$78.9M Buy
943,133
+92,067
+11% +$7.89M 0.04% 492
2013
Q2
$69.7M Buy
+851,066
New +$63.7M 0.04% 512

Other funds holding ELV

Morgan Stanley's ELV Position: Q1 2026 in Review

Morgan Stanley increased its Elevance Health (ELV) stake by 4.3% in Q1 2026, buying an estimated $35.5M and bringing the position to 2,629,104 shares worth $770M. The position accounts for 0.05% of the portfolio, ranked #388.

Morgan Stanley first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.74B in Q4 2023. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Morgan Stanley held 2,629,104 shares of Elevance Health worth $770M as of Q1 2026.
  • Morgan Stanley bought 107,981 Elevance Health shares in Q1 2026, an estimated $35.5M.
  • Elevance Health made up 0.05% of Morgan Stanley's portfolio in Q1 2026, its #388 holding.
  • Morgan Stanley first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
  • Morgan Stanley's Elevance Health position peaked at $2.74B in Q4 2023.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.